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Abstract
We report a novel computational method, RegNetDriver, to identify tumorigenic drivers using the combined effects
of coding and non-coding single nucleotide variants, structural variants, and DNA methylation changes in the DNase I
hypersensitivity based regulatory network. Integration of multi-omics data from 521 prostate tumor samples indicated
a stronger regulatory impact of structural variants, as they affect more transcription factor hubs in the tissue-specific
network. Moreover, crosstalk between transcription factor hub expression modulated by structural variants and
methylation levels likely leads to the differential expression of target genes. We report known prostate tumor
regulatory drivers and nominate novel transcription factors (ERF, CREB3L1, and POU2F2), which are supported
by functional validation.
Keywords: Tissue-specific regulatory network, Cancer drivers, Single nucleotide variants, Structural variants,
DNA methylation, Prostate cancer
Background
Cancer is a disease of the genome, characterized by un-
controlled growth and survival of damaged cells [1]. Pros-
tate cancer (PCa) is the second most common cancer in
men worldwide [2]. Whole-exome sequencing and whole-
genome sequencing (WGS) of tumors has revealed
recurrent genomic alterations in PCa [3–8]. Genomic
alterations range from single nucleotide variants (SNVs)
to large structural variants (SVs) [5, 9, 10]. SVs include
deletions, insertions, duplications, inversions, transloca-
tions, and other complex rearrangements. The most com-
mon genomic alteration identified in prostate tumors is
the fusion of the 5′ untranslated region of TMPRSS2 with
ERG caused by deletions or translocations, which is found
in 40–50% of samples [3, 11, 12]. Other frequent alter-
ations include: chromosomal deletions involving loss of
NKX3.1 [13, 14], PTEN [15–17], TP53, CHD1, or
CDKN1B [18]; genomic gains of chr 7 and 8q; and focal
amplifications of MYC, PIK3CA, FGFR1, and WHSC1L1
[3]. Additionally, recurrent SNVs have been identified in
SPOP, FOXA1, TP53, MED12, IDH1, and PTEN [3, 5–8].
These known genomic alterations affect the genes in-
volved in prostate development, cell cycle signaling, chro-
matin modification, androgen signaling, and many other
processes [4]. Further, these alterations lead to substantial
heterogeneity in tumor samples and have been used to de-
fine PCa molecular subtypes based on fusion of ETS fam-
ily genes (ERG, ETV, ETV4, or FLI1) and mutations in
SPOP, FOXA1, or IDH1 [3].
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Other than genomic changes, epigenetic alterations such
as changes in DNA methylation, histone modifications,
and chromatin organization (e.g., nucleosome remodeling
and chromatin looping) impact gene expression and play
an important role in the onset and progression of PCa
[19–21]. Among the different epigenetic changes, DNA
methylation is the most common and best characterized
in PCa [3, 22–24]. Aberrant DNA methylation (hyper- or
hypo-methylation) at promoter regions in PCa has been
reported to be associated with gene expression changes
[25]. For example, down-regulation of GSTP1 activity in
PCa due to DNA hyper-methylation in the promoter re-
gion has been associated with prostate carcinogenesis
[26]. Other genes that commonly exhibit hyper-
methylated promoters and have known implications in
prostate tumorigenesis include MGMT, CDKN2A, APC,
AR, and ER [22, 27]. Similarly, the high expression of
PLAU and CAGE genes in prostate cells due to promoter
hypo-methylation [23] has been associated with increased
tumor invasion and metastasis [22].
Although the individual lists of genetic and epigenetic
alterations have greatly enhanced our understanding of
prostate tumorigenesis, these events do not act in isola-
tion and it is important to interpret their integrative glo-
bal effects on differential gene expression in cancer. This
is because various events can alter the expression of a
gene (1) SNVs or SVs in (a) the coding sequence of the
gene, (b) the transcription factors (TFs) that regulate it,
or (c) the associated non-coding regulatory regions (pro-
moters and enhancers) or (2) epigenetic changes at the
promoters and enhancers. Previous studies have focused
on the identification of individual categories of alter-
ations that occur more than expected randomly, and
thus likely constitute drivers of tumorigenesis – for ex-
ample, SNVs [3, 6, 9, 28] or SVs [3, 11, 29]. However,
these alterations act in concert to influence tumor
growth and it is important to integrate the different cat-
egories of alterations to identify the top candidates that
are likely to play a major role in tumorigenesis by dysre-
gulating thousands of genes, termed regulatory drivers.
Here, we report a novel computational approach that
makes use of tissue-specific regulatory networks to
understand the global impact of genetic and epigenetic
alterations affecting both coding and non-coding cis-
regulatory regions (promoters and enhancers) and
identify the regulatory drivers of tumorigenesis. Tissue-
specific regulatory networks capture the molecular basis
of gene regulation at a systems level and offer a unique
means to understand the functional impact of genetic
and epigenetic changes in TFs, their target genes, and
non-coding cis-regulatory regions [30–32].
Regulatory networks are usually constructed using
data from chromatin immunoprecipitation sequencing
(ChIP-Seq) or gene co-expression assays. The networks
derived from ChIP-Seq data are limited by the availabil-
ity of antibodies corresponding to TFs and the difficulty
of interrogating multiple TFs in a tissue-specific manner.
The largest human regulatory network constructed using
ENCODE ChIP-Seq data consists of only 119 TF genes,
is not specific for prostate tissue, and does not contain
important PCa TFs, such as ERG and AR [30]. While regu-
latory networks based on gene co-expression overcome
the problem of studying one TF at a time, they suffer from
the limitation that network edges, which represent signifi-
cant co-expression relationships between genes (nodes),
often correspond to protein–protein interactions as op-
posed to regulatory interactions [33]. Networks can be
based on an alternative statistical measure, namely mutual
information to detect dependence between every pair of
genes from RNA expression [34–37]. However, the edges
in both co-expression networks and those based on mu-
tual information lack edge directionality (i.e., which TF
gene is the regulator and which gene is regulated) and do
not allow incorporation of cis-regulatory regions in the
network. Overcoming these limitations, we report the use
of DNase I hypersensitive sites (DHS) corresponding to
accessible regulatory DNA regions to study directed
tissue-specific regulatory interactions [38, 39]. Unlike pre-
vious studies, our approach for DHS-based network con-
struction is not restricted to TF–TF interactions [32],
rather we model the interactions of TFs with both TF and
non-TF target genes and incorporate regulatory regions
(promoters and enhancers) assisting those interactions.
We combined DHS data from prostate epithelial
cells with other functional genomics data from
ENCODE and the Roadmap Epigenomics Mapping
Consortium (REMC) [40] to construct a comprehensive
prostate regulatory network [40, 41]. Previous studies have
shown that genes encoding TFs often play an important
role in tumorigenesis [42–45]. Targeting TFs that regulate
a large number of genes (TF hubs) and act as drivers of
cellular transformation from normal to malignant state
can offer novel therapeutic options [42]. While ERG and
AR are well known TF genes that play an important role
in prostate tumorigenesis, a recent study has also reported
FOXM1 and a non-TF gene CENPF as master regulators
of PCa malignancy [46]. However, a comprehensive ana-
lysis connecting the tumorigenic genomic and epigenomic
alterations with prostate-specific TF hubs has not been
performed. Using our novel computational approach, we
first determined prostate-specific TF hubs and then ana-
lyzed WGS data from 188 primary PCa samples from the
International Cancer Genome Consortium (ICGC) and
other published studies [5, 9, 47] along with DNA
methylation data from 333 samples from TCGA [3]
to identify genetic and epigenetic alterations that alter
hub expression and cause large-scale network changes,
potentially driving the transformation of normal cells to a
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tumorigenic state. The large sample sizes used for this
analysis provided the statistical power to detect and
distinguish genes significantly altered by recurrent
SNVs, SVs, or DNA methylation changes in their cod-
ing or non-coding regions from the background of ran-
dom passengers.
Thus, we present a novel computational method that
integrates genetic and epigenetic data from tumor sam-
ples and interprets the combined effects of coding and
non-coding cis-regulatory regions significantly altered by
SNVs, SVs, and DNA methylation on the tissue-specific
regulatory network [5, 9, 48, 49].
Results
We developed a three-step computational model, RegNet-
Driver, for identifying genetic and epigenetic alterations
causing large perturbations in tissue-specific regulatory
network. The steps are: (1) construction of a tissue-
specific regulatory network using DHS data and identifica-
tion of TF hubs, (2) the identification of significantly
mutated, rearranged, and differentially methylated coding
and non-coding regulatory regions, and (3) the interpret-
ation of the global impact of genetic and epigenetic
alterations in the regulatory network (Fig. 1). We applied
our computational model on genetic and epigenetic data
from prostate tumor samples and identified regulatory
drivers of prostate tumorigenesis.
Construction of the tissue-specific regulatory network
using DHS data and identification of TF hubs
Mapping TF–target gene regulatory interactions in
prostate cells
Our pipeline for constructing the prostate network be-
gins by identifying active cis-regulatory regions in pros-
tate tissue. We identified 15,542 active promoters and
74,440 active enhancers using DHS in prostate epithelial
cells (Methods). These numbers are consistent with
current estimates of active promoters and enhancers in a
tissue: ~10,000–15,000 promoters [50, 51] and ~44,000–
294,000 enhancers [40, 52, 53] depending on the tissue
type. To uncover TF-DNA binding sites in these active
regulatory regions, we used the PIQ (Protein Interaction
Quantification) tool [54] and a curated collection of se-
quence binding motifs for 617 TFs [55]. We find enrich-
ment of 612 TF motifs in the active promoter and
enhancer regions. This knowledge of enriched TF bind-
ing motifs was used to create TF–promoter and TF–
enhancer edges in the regulatory network. The active
prostate promoters and enhancers with enriched TF
binding motifs were associated with their target genes to
Fig. 1 Flow chart of the three-step computational model for identifying genetic and epigenetic alterations causing large perturbations in the
tissue-specific regulatory network. Step 1 is construction of the tissue-specific regulatory network using DHS data and identification of TF hubs.
Step 2 identifies significantly mutated, rearranged, and differentially methylated coding and non-coding elements and step 3 combines the
output of steps 1 and 2 and outputs the effect of genetic and epigenetic alterations on TF hubs. DHS DNase I hypersensitive sites, REMC Roadmap
Epigenomics Mapping Consortium, SNV single nucleotide variant, SV structural variant, TF transcription factor
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model promoter–target gene and enhancer–target gene
interactions (Methods).
One enhancer can regulate the expression of multiple
genes [53] – we find in our network each enhancer is asso-
ciated with an average of three genes (Additional file 1:
Figure S1a). Similarly, multiple enhancers can regulate the
expression of a gene. In our prostate regulatory network,
each target gene is associated with an average of five active
enhancers (Additional file 1: Figure S1b). Thus, using our
pipeline, we generated an extensive prostate regulatory net-
work (Additional file 2), which contains 17,087 genes (in-
cluding 612 TFs) (Additional file 3: Table S1) and 1,209,599
unique directed TF–target gene interactions (Fig. 2).
Validation of prostate regulatory network
Although systematic validation of all interaction edges is
difficult due to the large scale of the network and our
limited understanding of the true network [56], a com-
mon approach is to use independent TF binding data
from ChIP-Seq experiments [57]. We assessed the edges
between TF and target genes using ChIP-Seq binding
peaks for nine TFs (androgen receptor or AR [58], CTCF
[59], ERG [29], ETS1 [60], ETV1 [61], GABPA [62],
GATA2[63], NR3C1 [64], and TCF7L2 [65]). We report
sensitivity, specificity, precision, and F score values for
the predicted TF–target gene edges (Additional file 3:
Table S2). For these nine TFs, we obtain an average sen-
sitivity of 0.64 and specificity of 0.68. We note that
ChIP-Seq data may not necessarily be the true gold
standard due to the possibility of some edges labeled
incorrectly as positive (non-specific TF binding) or nega-
tive (undetected regions), which can impact the sensitiv-
ity and specificity of our network [57].
We also compared the performance of our methodology
to construct the tissue-specific regulatory network with
another method [57]. Marbach et al. developed a network
compendium comprising 394 cell type- and tissue-specific
gene regulatory networks for human, including a prostate
epithelial cell network using TF sequence motifs from EN-
CODE with promoter and enhancer activity data from the
FANTOM project (http://regulatorycircuits.org) [57]. We
compared the area under the receiver operator character-
istic curve (AUROC), the area under the precision-recall
curve (AUPRC), and F score values of the Marbach
et al. predicted prostate TF–target genes with our
network predictions (Fig. 3, Additional file 1: Figure S2
and Additional file 3: Tables S2 and S3). Overall, we find
higher average AUROC, AUPRC and F scores from our
network for the TF–target gene edges compared to
Marbach et al. network (more details discussed in
Methods). Also, we obtained overall higher AUROC and
AUPRC values for RegNetDriver predicted TF–promoter
and TF–enhancer edges in comparison to Marbach et al.
(see Methods and Additional file 1: Figure S3).
The agreement of TF network edges with ChIP-Seq
binding peaks and the better performance of our net-
work in comparison to Marbach et al. provide validation
for our prostate regulatory network predictions and
demonstrate the potential of our DHS-based network
construction algorithm to recapitulate global transcrip-
tional regulatory interactions.
TF hubs are enriched for known cancer genes
We evaluated the degree centrality distributions of the
genes in our regulatory network to identify the hubs
(Additional file 1: Figure S4b, c). Hubs are defined as the
highly connected TF genes (top 25% out-degree central-
ity) that regulate the expression of thousands of down-
stream genes [48]. Our prostate regulatory network
consists of 153 TF hubs (Additional file 3: Table S4),
which are significantly enriched for known cancer genes
(odds ratio, OR = 2.24; p value = 0.00074) (Methods). In
particular, TFs previously implicated in PCa are hubs in
our network: ERG, ETV1, ETV4, NR3C1, NKX3-1,
ETV3, NRF1, TP53, STAT3, ETV5, MYC, and ETV6
[3, 4, 6, 9, 66]. Other than known PCa genes, our list of
TF hubs also contains novel candidates, which may have a
role in prostate tumorigenesis (Additional file 3: Table S4).
Our prostate regulatory network represents the flow of
information from TFs to target genes via regulatory ele-
ments and provides a list of regulatory TF hubs. Next,
we investigated the genetic and epigenetic alterations in
coding genes and non-coding cis-regulatory elements to
identify the ones that are likely to impact TF-hub ex-
pression and cause large-scale network changes.
Identification of significantly mutated, rearranged, and
differentially methylated coding and non-coding
regulatory regions
Different genetic and epigenetic events can trigger global
remodeling of the prostate regulatory network. In an at-
tempt to understand the combined effects of different
events, such as SNVs, SVs, and DNA methylation changes
on prostate transcriptional machinery, we analyzed data
from primary prostate tumor samples to identify signifi-
cantly mutated, rearranged, and differentially methylated
regions, respectively.
Significantly mutated coding and non-coding regions
(FSig-SNV method)
We performed a comprehensive analysis of somatic muta-
tions in WGS data from 188 primary prostate tumor sam-
ples from ICGC and other published studies [5, 9, 47]. We
developed the FSig-SNV (Functionally Significant Single
Nucleotide Variants) method, which analyzes the somatic
mutations in coding and non-coding (promoter and en-
hancer) regions to identify the elements that show more
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Fig. 2 Schematic of DHS-based prostate regulatory network. a Identification of active promoters and enhancers: promoters and enhancers active
in prostate tissue were identified by intersecting DHS from prostate epithelial cells with tissue-agnostic promoters and enhancers identified using
functional annotations from ENCODE, REMC, and GENCODE. b Predict TF binding sites: binding sites of 617 TFs in active prostate promoters and
enhancers were identified using 2065 motifs and PIQ. c Prostate Regulatory Network: the prostate regulatory network contains 17,087 genes (including
612 TFs), 15,542 promoters, 74,440 enhancers, and 1,209,599 unique directed TF–target gene interactions. For the purpose of presentation, we have
limited the number of network edges. DHS DNase I hypersensitive sites, PIQ Protein Interaction Quantification, REMC Roadmap Epigenomics
Mapping Consortium, TF transcription factor
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recurrent (present in multiple samples) and more func-
tional mutations than expected randomly.
Our method combines the functional impact and pos-
itional recurrence of the variants to compute a compos-
ite score for each element. The functional impact score
is computed using FunSeq2 [48, 67], a computational
framework for annotating and calculating the functional
impact score of coding and non-coding variants. FSig-
SNV then compares the calculated composite score with
a null background to compute p values. The null back-
ground is computed from random combinations of an
equal number of SNVs in the element [68, 69]
(Methods). The output of the method is a list of signifi-
cantly mutated coding and non-coding elements that
show a higher than expected frequency of functional
mutations across multiple tumor samples.
QQ plots show that the p values calculated using the
FSig-SNV method for coding regions, promoters, and
enhancers follow the expected uniform distribution
(Fig. 4a). Using FSig-SNV, we identified the coding re-
gion of a gene (SPOP), the promoters of three genes
(NBPF10, PDE4DIP and ZNF595), and the enhancer of a
gene (HM13) to be significantly mutated (Fig. 4a). Con-
sistent with previous PCa studies [3, 5, 6], SPOP is nom-
inated by FSig-SNV as the most significantly mutated
coding candidate (8% in our dataset).
In total, 42% of the tumor samples harbor at least one
mutation in a significantly mutated element: the coding
region of SPOP or the promoter of PDE4DIP, NBPF10, or
ZNF595, or the enhancer of HM13. We note that while
our analysis reveals the non-coding regions of PDE4DIP,
ZNF595, and HM13 as significantly mutated in PCa for
the first time, their coding regions have been previously
implicated in prostate or other cancers [70–73].
Significantly rearranged coding and non-coding regions
(FSig-SV method)
Given the important role of oncogenic fusions and
chromosomal rearrangements in PCa, we next identified
coding and non-coding regulatory regions significantly
altered by SVs across multiple tumor samples. Briefly,
our FSig-SV (Functionally Significant Structural Vari-
ants) method begins with the identification of elements
affected by deletion, insertion, duplication, inversion, or
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Fig. 3 a Area under receiver operator characteristic curve, b Area under precision-recall curve (AUPRC), and c F scores for TF–target gene edges
in the prostate epithelial networks of RegNetDriver (blue) and Marbach et al. (red). ChIP-Seq binding peaks of nine TFs (shown on the x-axis) and
promoter–gene and enhancer–gene annotations from both networks are used for network evaluation. ChIP-Seq-based targets using RegNetDriver
annotations are referred to as ChIP-RegNetDriver, shown in circles and targets using Marbach annotations are called ChIP-Marbach, shown in
triangles. Square data points correspond to mean values computed using ChIP-RegNetDriver and ChIP-Marbach targets. TF transcription factor
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Fig. 4 (See legend on next page.)
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translocation events. For each element, it counts the
number of samples that exhibit an SV event and com-
pares them with a null background generated by ran-
domly shuffling SV breakpoints, keeping SV length and
overall number of SVs in each chromosomal arm con-
stant (Methods). The output of the method is a list of
coding and non-coding elements that are rearranged
in more samples than expected randomly. We ana-
lyzed somatic SVs, which include copy number vari-
ants (such as deletions and duplications), and copy
number neutral variants (such as inversions, transloca-
tions, and other complex rearrangements), from 188
PCa whole-genomes from ICGC and other published
studies [5, 9, 47] (as discussed under FSig-SNV). Figure 4b
shows the QQ plots for coding regions, promoters, and
enhancers.
We identified 168 genes with significantly rearranged
coding regions. This includes genes already implicated in
prostate tumorigenesis, such as PTEN, ERG, TMPRSS2,
TP53, and FOXP1. In addition, we identified 169 genes with
significantly altered promoters and 187 genes with signifi-
cantly altered enhancers. Overall, 264 genes exhibit signifi-
cant rearrangements in their coding or non-coding regions.
Thus, using data from 188 whole genomes, we find that a
much larger number of coding genes and non-coding regu-
latory elements are affected by SVs (524) than SNVs (5) in
PCa (Table 1 and Additional file 4: Tables S5–S7).
Significantly differentially methylated promoters and
enhancers
DNA hyper-methylation at cis-regulatory regions is
mostly associated with down-regulation of gene expres-
sion, and hypo-methylation with up-regulation [74].
TCGA PCa study showed that genes silenced due to
promoter hyper-methylation are significantly enriched
for genes previously known to be differentially expressed
in PCa [3]. Using HumanMethylation450 (HM450) array
data corresponding to 333 TCGA primary prostate
tumor samples and the ELMER (Enhancer Linking by
Methylation/Expression Relationships) package [52], we
identified 4,591 hyper- and 1,177 hypo-methylated pro-
moter probes and 603 hyper- and 267 hypo-methylated
enhancer probes (Fig. 4c). Using mRNA expression data
from the tumor samples, we determined putative target
genes whose expression is modulated by differential
methylation of probes (Methods). We found 346 genes
significantly associated with hyper-methylated pro-
moters, 28 genes with hypo-methylated promoters, 53
genes linked with hyper-methylated enhancers, and 69
genes with hypo-methylated enhancers (Wilcoxon rank-
sum test, p value < 0.01) (Additional file 4: Table S8). In
total, 496 genes are associated with differentially methyl-
ated regulatory regions and are significantly enriched for
genes found to be differentially expressed in PCa relative
to normal samples (Methods, Fisher’s exact test, p
value = 3.77 × 10-9, OR = 1.74). In Fig. 4c, we show ex-
amples of genes whose expression is associated with
methylation at their regulatory regions. Thus, we find that
an even larger number of genes are affected by differential
methylation than by SVs or SNVs (Table 1).
The list of genes with significantly mutated or rear-
ranged coding or regulatory regions and those with
differentially methylated promoters or enhancers is pro-
vided in Additional file 4: Table S5. This list contains
both known cancer genes and novel candidates that may
play a role in prostate tumorigenesis. Next, we analyzed
the impact of these significant genetic and epigenetic
perturbations on the prostate regulatory network to
identify the regulatory TF drivers.
Interpretation of the global impact of genetic and
epigenetic alterations in the regulatory network
The results discussed under “Identification of signifi-
cantly mutated, rearranged, and differentially methylated
coding and non-coding regulatory regions” show the im-
pact of genetic and epigenetic alterations on individual
genes. We further analyzed the impact of these alter-
ations in the context of the prostate regulatory network.
Common effects of distinct genetic and epigenetic changes
on gene expression
To understand whether dysregulated gene expression
can be a consequence of the combined effects of genetic
and epigenetic changes, we analyzed the list of genes sig-
nificantly altered by SNVs, SVs, and differential methyla-
tion. Overall, 757 genes are significantly affected by
(See figure on previous page.)
Fig. 4 Significantly mutated, rearranged, and differentially methylated coding and non-coding regions. a QQ plots for significantly mutated
coding sequence (CDS), promoters, and enhancers using FSig-SNV. b QQ plots for significantly rearranged CDS, promoters, and enhancers using
FSig-SV. c DNA methylation changes and their association with gene expression. Left and middle: Significantly differentially methylated promoters
and enhancers. Violin plots show a significant difference in methylation levels (Wilcoxon test p value < 0.05) at hyper- and hypo-methylated
cis-regulatory regions (promoters and enhancers) between 333 tumor and 35 normal samples. Right: Scatter plots show examples of genes
differentially expressed due to a hyper-methylated promoter (PROM1) and a hypo-methylated enhancer (MTBP) in tumor vs. normal samples. MTBP and
PROM1 have been reported to be differentially expressed in TMPRSS2:ERG positive prostate tumors [122]. A significant decrease in PROM1 expression
in 152 TMPRSS2:ERG fusion positive TCGA samples (red) vs. normal (pink) is associated with a hyper-methylated promoter (cg04203238). A
significant increase in MTBP expression in ERG fusion positive samples (yellow) is associated with hypo-methylation in an enhancer (cg11476306). CDS
coding sequence
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genetic or epigenetic alterations. Out of these genes,
only three genes are affected by both genetic and epigen-
etic events: FAS, FAM3B, and TNFSF13. These three
genes are in deleted loci covering the entire gene body
and exhibit hyper-methylation in their promoter regions
(Fig. 5a). To analyze the combined effects of these differ-
ent events on gene expression, we used RNA-Seq, DNA
methylation, and deletion data from 333 TCGA tumor
samples. For FAS, we find 88 samples have undergone
gene deletion and 67 samples show significant hyper-
methylation in the promoter region. However, 93% of
these samples have the FAS gene altered by either
methylation changes or deletion and only six samples
exhibit both deletion of the gene and promoter hyper-
methylation (see the Venn diagram in Fig. 5b). This high
percentage of unique samples altered by each event sug-
gests that genetic and epigenetic events independently
lead to FAS dysregulation in PCa samples. Indeed, we
find down-regulation of FAS in samples with deletions
vs. without (p value = 0.0061) and in samples with pro-
moter hyper-methylation vs. without (p value = 7.43 ×
10-12) (Fig. 5c and Additional file 1: Figure S5). FAS
plays a central role in programmed cell death and is
important for regulating cell proliferation and tumor-
cell growth [75, 76]. We note that germline polymor-
phisms leading to its dysregulated expression have
been previously associated with a high risk of cancer,
including PCa [75, 77, 78].
We obtained similar results for FAM3B and TNFSF13,
i.e., a high percentage of unique samples altered by either
promoter hyper-methylation or deletion (Additional file 1:
Figure S6a and b). FAM3B and TNFSF13 also have known
implications in cancer [79, 80] and their altered
expression may have some role in prostate tumorigenesis.
These results demonstrate that distinct genetic and
epigenetic events can independently lead to the same ef-
fects on gene expression in PCa, though it is not common.
SVs have a stronger influence on TF hubs than SNVs and
DNA methylation
Overall, we observe more TF genes are affected by
methylation changes than SVs or SNVs (Table 1 and
Fig. 6). Altogether, 22 TF genes show significant differ-
ential methylation in promoter or enhancer regions,
while nine are significantly altered by SVs and none by
SNVs (Table 1). Although observed for the first time in
the genome-wide analysis of TF genes, this is consistent
with previous PCa studies, which report a low mutation
rate in prostate tumors compared to other tumor types
and found a high recurrence of SVs and DNA methyla-
tion changes [3, 25, 81]. However, going one step further,
we observe a stronger influence of SVs on TF hubs com-
pared to methylation changes or SNVs. Out of nine TF
genes altered by SVs, six are hubs (ERG, TP53, ERF,
SPI1, CREB3L1, and POU2F2), whereas among 22 TFs
with significant methylation changes, only three are TF
hubs (TFAP2A, TFAP2C, and NR3C1). Thus, we find
that TFs altered by SVs are significantly enriched for
hubs compared to TFs altered by methylation changes
(Fisher’s exact test: OR = 11.28, p value = 0.0068)
(Table 1). We note that apart from TP53 and ERG,
which are known PCa genes, our list of TF hubs altered
by genomic and epigenomic changes include TFAP2A
[82], CREB3L1 [83], and ERF [84], which have some re-
ported implications in prostate tumorigenesis.
Dysregulation of the central nodes in the network is
likely to produce global effects on prostate transcrip-
tional machinery and these numbers show that a larger
number of TF hubs are likely to be dysregulated by SVs
compared to methylation changes. Indeed, we find that
Table 1 Genes affected by genetic and epigenetic alterations in their coding and non-coding elements
SNV single nucleotide variant, SV structural variant, TF transcription factor
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five out of six TF hub genes affected by recurrent SVs
show differential expression between normal and tumor
samples (ERG, TP53, ERF, CREB3L1, and POU2F2) (see
Methods for p values, interaction edges shown in
Additional file 1: Figure S7). Altered expression of ERG
and TP53 due to gene fusions and deletions has already
been shown to play an important role in prostate
tumorigenesis [85, 86]. We propose that the dysregu-
lated expression of the remaining three TF hubs identi-
fied in our study (ERF, CREB3L1, and POU2F2) can also
lead to large-scale changes in the prostate regulatory
network, which in turn can play an important role in the
transformation of normal cells to a tumorigenic state.
Next, we performed functional validation to under-
stand the role of differential ERF expression in prostate
tumorigenesis.
Functional validation of novel prostate regulatory driver, ERF
ERG and ERF are members of the ETS family of TFs. ERG
is a transcriptional activator, whereas ERF is a tran-
scriptional repressor whose interaction with ETS
binding sites can suppress ETS-associated tumorigen-
esis [87, 88]. We observe a significant increase in ERG
expression and a significant decrease in ERF expression
due to SVs (Additional file 1: Figure S8). Also, we find
significant enrichment of common binding targets for
ERG and ERF in our prostate regulatory network (com-
mon targets = 3,061, Fisher’s exact test OR = 106.72 and
p value < 2.2 × 10-6). Based on these results, we hy-
pothesized that a decrease in ERF expression in pros-
tate tumor samples can cause activation of the ETS
transcriptional program similar to ERG activation. To
test our hypothesis, we used the ERF gene expression
signature generated from the lentiviral shRNA knock-
down and RNA-Seq analysis of immortalized prostate
epithelial cell line (LHS-AR) and a PCa cell line that
harbors oncogenic ERG rearrangement (VCaP) [89].
Among the top 100 up-regulated genes due to ERF
knockdown in the VCaP cell line (see Methods), 63 are
present in our prostate regulatory network. Genes up-
regulated due to ERF knockdown in the VCaP cell line
are significantly enriched among both ERF and ERG
a)
b)
c)
61682
Fig. 5 Effect of genetic and epigenetic alterations on gene expression. a Schematic showing the effect of deletion and hyper-methylation of the
promoter region on expression of FAS (enhancers are shown in bluish green and the promoter in brown). b Venn diagram showing the number
of samples affected by deletion (blue) and hyper-methylation of the promoter (red). c Violin plots showing the change in expression of FAS in
tumor samples with deletion (n = 88) and tumor samples with hyper-methylated promoters (n = 67)
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network predicted binding targets [Fisher’s exact test
OR = 2.38, p value = 0.00012 (ERF) and OR = 3.58, p
value = 5.7 × 10-7 (ERG)]. Similar results were obtained
for the LHS-AR cell line (Methods). The significant en-
richment of the ERF gene expression signature in ERF
and ERG binding targets validates our network predic-
tions and supports our hypothesis that differential ex-
pression of ERF due to SVs can activate the ETS
transcriptional program in prostate tumor samples.
This functional study demonstrates the strong poten-
tial of our computational method to identify novel regu-
latory drivers of tumorigenesis.
Network propagation of differential TF hub expression via
methylation changes
Together, we find 7,675 differentially expressed genes in
PCa samples relative to normal (Methods). However, it
is unknown whether it is the genomic sequence changes
or epigenetic alterations that initiate the cascade of gene
expression changes in the prostate regulatory network.
The reversible nature of DNA methylation has attracted
much attention towards understanding the mechanism by
which it is regulated by TF binding. Whether methylation
at TF binding sites is a consequence of TF gene expression
or methylation gain is a cause for evicting TF remains un-
clear [90–92]. Based on the former hypothesis, multiple
studies have proposed several models that have linked TF
binding with acquisition or loss of methylation at
regulatory elements [90–93]. We investigated the relation-
ship between TF hub expression and DNA methylation at
its binding sites. Using DNA methylation and expression
data from 333 TCGA tumor samples, we calculated the
correlation between the expression of six TF hub genes
that are significantly altered by SVs (ERG, TP53, POU2F2,
SPI1, CREB3LI, and ERF) and average DNA methylation
(β values) at differentially methylated probes within
specific TF motifs. We find a significant association (p
value < 0.05) between expression and average DNA
methylation for three out of six TF hubs (ERG,
POU2F2, and SPI1). This significant correlation hints
towards DNA methylation as a dynamic process that
can be programmed to respond to changes in TF
expression (Methods) (Additional file 1: Figure S9).
Moreover, these results suggest that changes in TF hub
expression due to SVs can trigger epigenetic changes at
their binding sites in cis-regulatory regions, which
would in turn lead to differential expression of their
associated genes.
C
P
E       
C
P
E       
P
E      
P
E
SNVs
SVs
Hypo-methylation
Hyper-methylation
Fig. 6 Genomic landscape of prostate cancer. Green bars represent genes with significant SNVs in the coding sequence (C), promoter (P), and
enhancer (E) regions, blue bars correspond to genes with significant SVs in coding sequence, promoter, and enhancer regions, yellow bars show
genes with hypo-methylated promoters and enhancers, and red indicates genes with hyper-methylated promoters and enhancers. The genomic
location of six TF hubs (blue) affected by SVs is shown in the outer ring. TF transcription factor
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In our study, we observe that more TF hubs are per-
turbed by SVs than SNVs or DNA methylation, even
though a larger number of genes are affected by epigen-
etic alterations. Significant associations between TF hub
expression and methylation changes indicate a possible
mechanism for network propagation of differential hub
expression. We propose SVs as the initiators that per-
turb the expression of hubs and DNA methylation
changes as the propagators of gene expression changes
in the prostate regulatory network. This model would
explain the larger number of TF hubs altered by SVs but
overall a larger number of genes affected by methylation
changes. However, since correlation does not imply dir-
ect causation, we functionally validated our hypothesis
that altered expression of a TF hub can influence DNA
methylation by Enhanced Reduced Representation Bisul-
phite Sequencing (ERRBS).
Functional validation of impact of SVs on global DNA
methylation
To substantiate our hypothesis that genetic changes such
as SVs may be initiators that trigger changes in DNA
methylation, we used the ERRBS assay for functional val-
idation. ERRBS is a genome-wide single-base resolution
DNA methylation assay that provides high coverage of
CpGs [94–96]. Out of the six TF hub genes that are per-
turbed by SVs, ERG is rearranged at the highest fre-
quency (~45% of tumor samples). ERG rearrangements
result in its overexpression. To replicate the impact of
SVs, we used two stable isogenic benign prostate epithe-
lial cell lines (RWPE1), which only differ with respect to
ERG expression [97]. We used RWPE1-GFP (control)
and RWPE1-ERG cell lines to see if ERG overexpression
can lead to global methylation changes. To estimate the
methylation levels, we performed ERRBS for both
RWPE1-ERG and RWPE1-GFP cells. ERRBS provided
tenfold sequencing coverage on >2.5 million CpG sites
genome-wide for each cell line. By analyzing methylation
levels of all CpG sites, we observe an overall significant
difference in the DNA methylation level of the RWPE1-
ERG cell line in comparison to the control. There are
226,677 differentially methylated CpGs (q value < 0.01), in-
cluding 105,720 CpGs that are hyper-methylated and
120,957 CpGs that are hypo-methylated in the RWPE1-
ERG cell line vs. the control (Additional file 1: Figure S10).
Figures 7a and b show the distribution of hyper- and hypo-
methylated CpGs on each chromosome. Overall, we find
~9% of the genome is differentially methylated as a result
of ERG overexpression in RWPE1-ERG cells. Furthermore,
we used a site-specific methylation validation assay (EpiTY-
PER MassARRAY system) to specifically measure the
methylation at the top 17 hyper-methylated CpGs identi-
fied from the ERRBS data in the RWPE1-ERG cells vs.
GFP. We see a significant increase in the methylation for
RWPE1-ERG cells with respect to GFP for all the 17 CpG
sites, providing independent validation for the ERRBS re-
sults (Figs. 7c and d) (Wilcoxon test, p value = 3.28 × 10-10,
Additional file 4: Table S9).
These results demonstrate that, within controlled iso-
genic conditions, global methylation changes are associ-
ated with ERG overexpression. Therefore, our findings
provide further insights about the relation between TF
hub expression and global methylation levels in prostate
cells (discussed above), corroborating the role of gen-
omic alterations in mediating changes in the epigenome.
Computational pipeline to identify regulatory drivers
The protocol discussed in this work has been converted
into a computational pipeline, RegNetDriver, to identify
genetic and epigenetic alterations in the coding and non-
coding regulatory regions of the tumor genomes and
analyze their effects on tissue-specific regulatory networks
(khuranalab.med.cornell.edu/RegNetDriver.html) (Fig. 1).
In this study, we analyzed PCa genomes, but the pipeline
can be easily used for different cancer types. We expect
that analyses using the pipeline will reveal the varied roles
of coding vs. non-coding and genetic vs. epigenetic alter-
ations in diverse tumor types.
Discussion
Previous studies have identified genetic and epigenetic
differences in tumor vs. normal cells but translation of
this information to an understanding of the processes in-
volved in tumor development and progression still re-
mains a major challenge. Progression of normal cells to
a tumorigenic state involves differential expression of
thousands of genes due to genetic and epigenetic
changes [98, 99]. In this study, we present a computa-
tional framework to construct a tissue-specific regulatory
network and use it to understand the global impact of
genetic and epigenetic alterations on differential gene
expression associated with cancer. To construct the
prostate regulatory network, we utilized functional gen-
omics data from ENCODE and REMC to associate
prostate-specific promoters and enhancers to their target
genes and predicted enrichment of TF motifs within
these regulatory elements. Using this network, we identi-
fied TF hubs, which are predicted to regulate the expres-
sion of thousands of genes. Genetic and epigenetic
changes that impact TF hubs can cause large-scale
changes in the network, which in turn can drive the
transformation of normal cells into a tumorigenic state
[100, 101]. Identification and subsequent activation/in-
activation of tumorigenic TF hubs by small molecules
can impair tumor growth and development, as shown
recently for ERG inhibition by dexamethasone [102].
Despite the challenges associated with considering TFs
as drug targets [103], recent work by Gayvert et al.
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demonstrates the use of a computational drug-
repositioning approach for targeting TF activity using
small molecules [102]. Thus, TF hubs predicted to be as-
sociated with tumor progression by our approach can be
potential novel therapeutic targets for cancer drug
studies.
We identified 153 TF hubs in the prostate regulatory
network. These are significantly enriched for known PCa
genes and are predicted to play an essential role in
maintaining the prostate transcriptional machinery. The
prostate regulatory network and the associated hubs dis-
cussed in this work will be a useful resource for further
investigations of other diseases involving the prostate tis-
sue beyond the current study. In this study, we inte-
grated our knowledge of the prostate regulatory network
from normal cells with WGS and DNA methylation data
from primary prostate tumors to analyze systematically
how genetic and epigenetic alterations in coding and
a)
c)
b)
d)
Fig. 7 Overexpression of ERG causes global methylation changes. a Percentage of hyper-methylated (red) and hypo-methylated (yellow) regions
out of all covered CpGs for each chromosome in the RWPE1-ERG cell line. b Chromosome ideogram showing sites of differential methylation in
the RWPE1-ERG cell line. Hyper-methylated CpGs (red) and hypo-methylated CpGs (yellow). c Percentage methylation difference of 17 targeted
sequences in the isogenic RWPE1 cells (+/- ERG), measured by the EpiTYPER MassARRAY assay. The thick red outline boxes represent the difference
in methylation ratios between RWPE1-ERG and RWPE1-GFP measured on a sequence containing only the targeted CpG. The red boxes with a light
outline correspond to an average of methylation ratios on a sequence containing two to four CpGs including the targeted one. For each targeted
sequence, the methylation value has been measured in duplicate as shown in (d), except when the composition of the sequence did not allow it
(single value for the sequences 2, 8, 10, 12, 13, 16, and 17). d Each CpG is represented by a color-coded circle depending on its methylation ratio.
Yellow represents a low level of methylation, red represents a high level of methylation, and grey corresponds to unanalyzed CpGs. The values for
the methylation ratio of CpG #4 in sequence 9 determined on both forward and reverse strands are shown in (c)
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non-coding regions impact TF hubs and rewire the regu-
latory network in tumor cells. Using novel computa-
tional approaches (FSig-SNV and FSig-SV), we identify
known PCa genes that are significantly mutated by SNVs
(SPOP) or rearranged by SVs (TMPRSS2, ERG, PTEN,
CHD1, NKX3-1, and TP53) and predict novel candidate
genes with significant SNVs or SVs in their coding or
non-coding regions (promoters and enhancers). More-
over, by analyzing DNA methylation profiles from tumor
vs. normal samples, we identified genes with differen-
tially methylated promoters and enhancers across mul-
tiple tumor samples. This repertoire of genes with
substantial genetic and epigenetic alterations is a useful
resource of potential drivers whose role in prostate
tumorigenesis can be further explored. In our work, we
focused on TF hubs that show enrichment of genetic or
epigenetic changes in their coding or non-coding regions
and can act as regulatory drivers.
We find that overall a higher number of genes exhibit
significant differential methylation at promoters and en-
hancers than those that are significantly mutated or rear-
ranged. However, TFs that are altered by SVs are
significantly enriched for hubs compared to TFs altered
by methylation changes, suggesting that SVs play a piv-
otal role in PCa development by causing larger perturba-
tions in the regulatory network compared to SNVs and
methylation changes. The TF hubs that show differential
expression due to SVs are ERG, TP53, POU2F2, CRE-
B3LI, and ERF. Out of these, ERG and TP53 are known
PCa genes and we propose that POU2F2, CREB3L1, and
ERF can also play an important role in prostate tumori-
genesis. Functional validation supports the hypothesis
that ERF down-regulation leads to activation of the ETS
transcriptional program that mediates cell invasion and
tumor development. Very recently, a study of the
exomes of African-American PCa patients suggested the
role of ERF as a prostate tumor suppressor gene [89].
This study by Huang et al. provides independent valid-
ation of the predictions of our method and shows its im-
mense utility in identifying novel cancer drivers.
Based on the DNA methylation changes observed on
ERG overexpression, we propose a model to explain the
consequences of TF hub dysregulation on the prostate
regulatory network. In this model, crosstalk between TF
hub expression (modulated by SVs) and DNA methyla-
tion allows global expression changes in the network.
Previous studies have discussed multiple models to ex-
plain the crosstalk mechanism between TF expression
and DNA methylation at its binding sites. One such
model proposed that CpG islands at promoters can be
protected from DNA methylation by TF binding [91]. In
this model, higher TF expression would lead to in-
creased recruitment of histone H3 lysine 4 (H3K4)
methyltransferase, which protects the bound regions
from methylation [91]. On the other hand, higher TF ex-
pression has also been associated with hyper-
methylation [104, 105]. In this case, TF association with
DNA methyltransferases promotes methylation at the
bound regions. Thus, altered TF expression can be asso-
ciated with both hypo- and hyper-methylation depend-
ing on the TF and the physiological context [91]. We
propose that SVs may be the initiators that perturb the
expression of hubs and DNA methylation changes can
be the propagators of gene expression changes in the
regulatory network. We note that the functional valid-
ation in this study analyzed the consequences of ERG
and ERF expression changes on DNA methylation and
downstream gene expression respectively, but future
work can probe the direct impact of SVs on methylation
and target gene expression.
The framework proposed in this study can be used to
analyze other cancer types. We expect that our computa-
tional approach, RegNetDriver (provided at khuranalab.-
med.cornell.edu/RegNetDriver.html), will be extremely
useful for analyzing the ~2,800 tumor whole genomes,
transcriptomes, and epigenomes of 40 tumor types from
the upcoming Pan-Cancer Analysis of Whole Genomes
project [106].
Conclusions
We provide a computational framework, RegNetDriver, to
infer the global impact of tumorigenic genetic and epigen-
etic alterations in the tissue-specific network and identify
regulatory cancer drivers. The application of our method
on PCa data shows that SVs have a stronger regulatory
impact than SNVs and methylation changes. TF hub ex-
pression modulated by SVs can, in turn, lead to methyla-
tion changes. We identify known regulatory drivers (ERG
and TP53) and nominate novel TF genes (ERF, CREB3L1,
and POU2F2) that are significantly rearranged across mul-
tiple PCa samples and predicted to cause dysregulation of
thousands of genes. Functional validation of ERF supports
its role in prostate tumorigenesis by activation of the ETS
transcriptional program. RegNetDriver can be used to
analyze other cancer types, and we expect SNVs, SVs, and
methylation changes can play roles of varied importance
in different tumor types and tissues.
Methods
The DHS-based prostate regulatory network
The gene expression program of a cell depends on the
complex binding patterns of the TFs at the regulatory
DNA [38, 54]. In our work, we have used DHS data from
ENCODE for epithelial cells from the prostate (https://
www.encodeproject.org/experiments/ENCSR000EPU/)
along with GENCODE annotations [107], functional an-
notations from ENCODE [41], data from REMC [40], and
position weight matrices for TF motifs from ENCODE
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[55] to construct a prostate regulatory network. In the fol-
lowing section, we describe the different steps involved in
construction of the prostate network.
Identification of promoters and enhancers
We used tissue-agnostic regulatory elements and their
association with target genes as described in the Fun-
Seq2 protocol [67]. GENCODE v16 annotations were
used and promoters are defined as being -2.5 kb from a
transcription start site (TSS). To define tissue-agnostic
enhancers, we used functional elements identified by
ENCODE, which include regions of open chromatin as-
sociated with histone marks (H3K4me1, H3K4me2, and
H3K27ac) and significantly enriched for ChIP-Seq iden-
tified TF-motifs [41]. Our list of tissue-agnostic en-
hancers also includes regions of open and accessible
chromatin where transcription-related factors can easily
bind even without cognate sequence motifs, which are
defined as regions with a high occupancy of TFs (HOT)
in the work of Yip et al. [108]. All regulatory elements
that are at least 1 kb from the closest gene according to
GENCODE annotations were annotated as enhancers [67].
To associate enhancers with their potential regulatory tar-
gets, we considered all candidate target genes within 1 Mb
from enhancer regions. Correlations were calculated be-
tween the activity/inactivity signal at the enhancer region
and expression at candidate target genes. Enhancer histone
marks, such as H3K4me1 and H3K27ac, were considered
as activity signals and DNA methylation data were used as
inactivity signals. If there were significant correlation
values, the matches were called enhancer–target gene
pairs. Bisulfite sequencing, ChIP-Seq, and RNA-Seq data
from REMC across multiple tissues were used to calculate
correlations between activity/inactivity signals and expres-
sion data [67] (see Fu et al. [67] for more details).
To define active prostate promoters and enhancers,
we intersected tissue-agnostic promoters and en-
hancers with DHS of prostate epithelial cells obtained
from ENCODE (https://www.encodeproject.org/experi-
ments/ENCSR000EPU/). We found 15,542 active prostate
promoter regions and 74,440 enhancer regions. In the
next step, we identified TF motifs enriched in these active
prostate promoters and enhancers.
Prediction of TF binding motifs
We used the PIQ software [54] to predict TF binding in
the DHS data. PIQ uses machine learning to normalize
input DHS data and predict TF binding by detecting the
shape and magnitude of DNase profiles specific to a TF
[54, 109]. It takes as input DNase-seq experiment data,
the genome sequence of the organism assayed, and a list
of TF motifs represented as position weight matrices.
We provided PIQ with DHS data from epithelial cells of
the prostate, the human genome sequence, and 2,065 TF
motifs for 617 TFs from ENCODE [55]. The output of
PIQ is the probability of a TF binding at a motif in the
genome. We selected all the active prostate promoters
and enhancers with the predicted probability for the TF
binding at the motif being ≥0.7. We found significant
enrichment of 612 TF motifs in the active promoter and
enhancer regions. This information was used to generate
TF–promoter and TF–enhancer edges in our network.
There are 629,263 TF–promoter edges and 267,415 TF–
enhancer edges in our network. In the last step, we com-
bined the results of steps 1a (Identification of promoters
and enhancers) and 1b (Prediction of TF binding motifs)
to put together a prostate regulatory network.
TF–target gene interactions
All the active prostate promoters and enhancers enriched
for TF binding motifs are used to make connections be-
tween TFs and target genes. We used information of pro-
moter–target gene and enhancer–target gene pairs from
step 1a (Identification of promoters and enhancers) and
TF binding motifs enriched in these regulatory elements
from step 1b (Prediction of TF binding motifs) to make
TF–target gene edges. The output of this three-step proto-
col is an extensive prostate regulatory network, where
nodes represent TFs, target genes, and regulatory regions
(promoters and enhancers). The edges correspond to
interactions between these nodes, i.e., TF–promoter, TF–
enhancer, promoter–target gene, and enhancer–target
gene. The complete prostate network contains 629,263
TF–promoter edges, 267,415 TF–enhancer edges, 15,465
promoter–target gene edges, and 69,422 enhancer–target
gene edges. We used a simplified form of the prostate
regulatory network for the degree centrality analysis dis-
cussed in this work. The simplified prostate network con-
tains only TF–target gene interactions. There are 17,087
genes in the prostate network, which includes 612 TFs.
These 612 TFs are connected to target genes via 1,209,599
unique directed TF–target gene interactions.
Validation of TF–target gene edges in the network
To validate the TF–target edges in the prostate regulatory
network, we used ChIP-Seq data for nine TFs available from
prostate tissues or cell lines (Additional file 3: Table S2).
The dataset includes ChIP-Seq binding peaks for the AR
from normal prostate tissue and CTCF binding peaks
from prostate epithelial cells, while for the remaining TFs
we used the available ChIP-Seq peaks from different PCa
cell lines. The ChIP-Seq assay provides TF-bound regions
in the genome. We intersected these TF-bound regions
with all promoters and enhancers and connected them to
the target genes using the same approach as defined in
step 1a (Identification of promoters and enhancers). The
ChIP-Seq-based targets are used as the gold standard and
TF–target gene edges are defined as positive if they occur
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in ChIP-Seq-based targets and negative otherwise. Thus,
in our analysis, true positives (TP) refers to predicted TF–
target genes, which are also TF ChIP-Seq-based targets,
false positives (FP) are predicted targets that are not
ChIP-Seq-based targets and false negatives (FN) are ChIP-
Seq-based targets not predicted by our network. Sensi-
tivity (true positive rate or recall) = TP/(TP + FN),
specificity (true negative rate) = TN/(TN + FP), preci-
sion (positive predictive value) = TP/(TP + FP), and F
score = 2 × ((precision × recall)/(precision + recall)).
Our ChIP-Seq dataset includes AR and ERG binding
peaks. AR and ERG play pivotal roles in prostate tumori-
genesis [29, 85, 110]. AR activity is central for overexpres-
sion of most ETS genes such as ERG and ETV1, which are
fused with androgen-regulated promoters in prostate
tumors. Overexpression of ERG due to TMPRSS2:ERG fu-
sion results in increased cell invasion and promotes PCa
[29]. Differential AR activity has been shown to be associ-
ated with prostate tumor subtypes, such as those based on
SPOP and FOXA1 mutations [3]. Given the importance of
AR in prostate, we validated our network-predicted AR
edges using ChIP-Seq data. We overlapped 8,151 AR
ChIP-Seq binding peaks from normal prostate tissue
(GSM1358399) with 81,626 promoters for different gene
isoforms and 769,538 enhancers with gene links. There
are 3,759 ChIP-Seq-based AR targets. AR shares transcrip-
tional targets with other members of the nuclear hormone
receptor family [111]. Therefore, to compare AR binding
targets predicted with RegNetDriver with AR ChIP-Seq-
based targets, we considered both AR and NR3C1 motifs.
We compared 8,931 AR targets in the prostate network
against 3,759 AR ChIP-Seq-based targets from normal
prostate tissue and obtained a sensitivity of 0.716, specifi-
city of 0.618, and precision of 0.301 (Additional file 3:
Table S2). Also, the predicted AR targets include some of
the known target genes such as FGF8, CDK1, CDK2,
PMEPA1, TMPRSS2, SLC43A1, KLK3, KLK4, SLC45A3,
CHD1, KIF1A, PRKCD, FZD9, CLDN4, MAFG, KIAA1217,
OAT, TRPV3, SIRT7, GSTT2, HERC3, ELL2, CENPN,
MED28, ACSL3, GNMT, ABCC4, PTGER4, and CRELD2
[3, 29, 85, 112, 113]. Moreover, it has been reported that
AR and ERG co-occupy target loci in PCa cell lines and
tissues [29]. We compared 8,931 AR edges with 5,103
ERG edges in the prostate network and found that 3,443
target genes are common. We found significant enrich-
ment for common AR and ERG targets (hypergeometric
distribution test, p value = 1.5 × 10-151). Additional file 3:
Table S2 contains the results of network validation.
Network comparison
We compared the performance of our prostate regula-
tory network with the prostate epithelial cell network of
Marbach et al. for the nine TFs with available ChIP-Seq
binding peaks. To evaluate TF–target gene edges, we
overlapped the TF ChIP-Seq peaks with all promoters
and enhancers and then evaluated them using the con-
nections between promoter/enhancer and target genes
obtained both from RegNetDriver (ChIP-RegNetDriver
targets) and Marbach et al. annotations (ChIP-Marbach
targets). Due to the unavailability of a true gold standard
dataset for promoter–gene and enhancer–gene links, we
evaluated TF–target edges for the nine TFs in RegNet-
Driver and the Marbach et al. network using both ChIP-
RegNetDriver and ChIP-Marbach as gold standards.
Figures 3a and b show the AUROC and AUPRC for TF–
target genes edges in the prostate regulatory networks
from RegNetDriver (blue) and Marbach et al. (red). In
Fig. 3, circular data points represent network TF–target
gene edges evaluated using ChIP-RegNetDriver targets
and triangular data points represent network TF–target
gene edges evaluated using ChIP-Marbach targets. We
find higher AUROC and F scores for RegNetDriver for
eight out of nine TFs using both ChIP-RegNetDriver tar-
gets and ChIP-Marbach targets (Figs. 3a, c). The mean
values of AUROC and F scores computed using ChIP-
RegNetDriver and ChIP-Marbach targets are higher for
all nine TFs for RegNetDriver compared to Marbach
(Fig. 3; blue square boxes represent mean values for
RegNetDriver and red square boxes for Marbach). For
AUPRC, we find that network annotations for generating
ChIP-Seq-based TF–targets provide an additional advan-
tage to the networks, which show higher AUPRC values
for their respective annotation set. However, RegNetDri-
ver shows higher mean AUPRC for seven out of nine
TFs though the mean AUPRC values for RegNetDriver
and Marbach are more similar than AUROC or F scores
(Fig. 3b). Overall, these results demonstrate the ability of
a DHS-based network to recover more reliably true
prostate regulatory interactions.
We also evaluated the predicted TF–promoter and
TF–enhancer edges using ChIP-Seq binding peaks. We
overlapped ChIP-Seq peaks for the nine TFs with all
promoters and enhancers. We defined an edge as posi-
tive if there was a TF ChIP-Seq peak overlapping the
regulatory element and negative otherwise. Additional
file 1: Figure S3 shows the AUROC and AUPRC for
TF–promoter and TF–enhancer edges in the prostate
networks of RegNetDriver and Marbach. For eight out
of nine TFs, we see higher AUROC and AUPRC for
RegNetDriver TF–promoter edges in comparison to
the Marbach et al. network. The AUROC is also
higher for eight TFs for TF–enhancer edges in
RegNetDriver while AUPRC is higher for five TFs and
very similar (maximum difference = 0.05) for four TFs
(Additional file 1: Figure S3). We provide details of
the files used for evaluation of the Marbach et al.
prostate regulatory network in the Additional file 1:
Supplementary text.
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Regulatory TF hubs are enriched for known cancer genes
We used the prostate regulatory network to identify TF
hubs, which are defined as the top 25% of the highest
out-degree TFs [48]. Out-degree is the number of out-
going edges per node. There are 153 TF hubs in our
prostate regulatory network (Additional file 3: Table S4).
Next, we looked for cancer genes in our list of TF hubs.
In total, 573 genes were annotated by the Sanger Center
as causally implicated in oncogenesis (Cancer Gene Cen-
sus; http://cancer.sanger.ac.uk/census/) and 31 out of
153 TF hubs are known cancer genes. Fisher’s exact test
was applied to test the hypothesis that TF hubs are sig-
nificantly enriched for known cancer genes (OR = 2.24; p
value = 0.00074).
Significant genomic alterations
To identify significantly mutated coding and non-coding
elements (promoters and enhancers), we developed a
novel computational method called FSig-SNV, which
uses the functional impact and positional recurrence of
the variants present in both coding and non-coding re-
gions. For functional annotation, the method uses Fun-
Seq2 [67] to annotate and calculate the functional bias
score of each variant. FunSeq2 uses a weighted scoring
scheme that takes into account features such as the
functional annotation of variants; the presence of vari-
ants in sensitive, ultra-sensitive, ultra-conserved, and
HOT regions; the nucleotide-level impact of regulatory
variants, which includes the motif-breaking and motif-
gaining score; and the network properties of variant-
associated genes [48, 67]. This weighting method pro-
vides FunSeq2 with the ability to prioritize cancer som-
atic functional mutations better relative to other
methods [67, 114].
The positional recurrence of a variant is defined as the
number of tumor samples with the same mutated pos-
ition. At each mutated position (i) in the genome, we
multiplied the positional recurrence (W) and functional
impact score (FS) to get a positional FSig-SNVpos score:
FSig‐SNVpos ¼ Wi  FSi:
A summation of FSig-SNVpos for all the variants in an
element (coding, promoter, or enhancer) is defined as
the FSig-SNV score:
FSig‐SNV score ¼
Xn
i¼0Wi  FSi
where n is the total number of variants in an element.
To assess the significance of the FSig-SNV score for
each coding and non-coding element, we perform a per-
mutation test. In the permutation test, the observed
FSig-SNV score for an element is compared with a
null distribution of permuted FSig-SNV scores and
the p value is calculated. Null distributions specific to
coding and non-coding elements are generated by ran-
domly sampling the same number of positional scores
(FSig-SNVrpos scores, where rpos refers to random pos-
itional scores) within the same genomic element. Next, we
sum FSig-SNVrpos scores into an aggregate FSig-SNVrandom
score. Studies have shown that the mutation rate varies
across the mammalian genome and late-replicating regions
are associated with a higher mutation rate [68, 115, 116].
The p value of the test element is calculated using
P ¼
1þ
XN
n¼1F Xn≥X0ð Þ
N þ 1 :
The output of function F is 1 when Xn is bigger than
or equal to X0, otherwise it is 0. N is the number of
sampling iterations (default = 106). X0 is the observed
FSig-SNV score for a coding or non-coding element of a
gene and Xn is the FSig-SNVrandom score. We use the
Benjamini and Hochberg method for multiple hypothesis
testing (q value ≤ 0.05). The output of the method is a
list of genes with significantly mutated coding, and
promoter or enhancer elements.
We developed the FSig-SV method to identify signifi-
cantly rearranged coding and non-coding elements. The
term “rearranged” refers to SVs, including deletions, in-
sertions, duplications, inversions, and translocations. To
find rearranged regions within each chromosome, we
first generated a list of coding and non-coding regions
(promoter and enhancer) altered by different SVs. Next,
we counted the number of samples with SVs affecting
the listed coding and non-coding regions. In this way,
we know the number of samples with rearranged coding
and non-coding regions in each chromosome. To iden-
tify significantly rearranged regions in each chromo-
some, we simulate a background distribution of SVs by
randomly shuffling breakpoints keeping the total num-
ber of samples, number of SVs per chromosome, and
length of SVs constant. For each coding and non-coding
element within a chromosomal arm, FSig-SV compares
the number of samples affected in simulated data with
that observed and computes p values. The formula for
the p value calculation is the same as that discussed
above for FSig-SNV, where N corresponds to the num-
ber of sampling iterations (default 103), X0 is the number
of SVs in a coding or non-coding element, and Xn is the
number of random SVs in the element. The Benjamini
and Hochberg method was used for multiple hypothesis
testing (q value ≤ 0.01). The output of the method is a
list of genes with significantly rearranged coding or non-
coding elements.
For the above analysis, we used somatic SNVs and
somatic SVs from WGS data of 188 primary prostate
adenocarcinomas. These 188 primary PCa samples in-
clude 124 PRAD-CA samples from ICGC [47] (https://
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dcc.icgc.org/projects/PRAD-CA), 57 samples from the
work of Baca et al. [9], and seven samples from Berger et al.
[5]. We used 912,004 SNVs and 3,888 SVs from PRAD-CA
samples (n = 124) and 350,049 SNVs and 6,465 SVs (n = 64)
from the Baca et al. and Berger et al. samples.
DNA methylation
We used TCGA level 3, Illumina Infinium Human-
Methylation450 (HM450) array data corresponding to
333 primary prostate samples, 35 normal samples, and
the ELMER package [52] for identifying differentially
methylated promoter and enhancer regions. To define
promoter probes, we used the promoter definition of
being -2.5 kb from a TSS (as discussed above in Identifi-
cation of promoters and enhancers section). Out of
485,512 array probes, 167,284 were defined as promoter
probes and 20,094 probes overlapped with enhancer re-
gions (see Identification of promoters and enhancers
section for the enhancer definition). The amount of
DNA methylation at each CpG is referred to as the β
value, where β =M/(M + U) and M is the methylated al-
lele intensity and U is the unmethylated allele intensity.
The ELMER package uses a t-test to identify promoter
and enhancer probes that are significantly hyper-
methylated or hypo-methylated relative to normal samples
(n = 35 samples). To identify hypo-methylated probes,
ELMER compares the 20% of normal samples with the
lowest methylation to the 20% of tumor samples with the
lowest methylation and performs an unpaired one-tailed
t-test. Similarly, to identify hyper-methylated probes, it
compares the 20% of the highly methylated normal and
tumor samples [52]. For additional stringency, ELMER
considers a probe as differentially methylated if the methy-
lation difference is greater than 0.3 (|μnormal – μtumor| > 0.3)
and the one-tailed t-test q value < 0.01. Apart from identi-
fying differentially methylated promoter and enhancers,
ELMER correlates the state of these regions with the ex-
pression of the nearby genes to identify transcriptional
targets [52]. The output of the package is a list of signifi-
cantly differentially methylated promoter and enhancer
probes (q value ≤ 0.01) and their significantly associated
target genes (q value ≤ 0.01).
To generate scatter plots for visualizing the effect of
the expression of TF hubs on global methylation, we
used level 3 HM450 PRAD DNA methylation data for
333 TCGA prostate samples and log2-transformed level
3 PRAD TCGA RNA-Seq RSEM data.
Common effects of genetic and epigenetic alterations on
differential gene expression
To analyze that impact of SVs and promoter DNA
hyper-methylation on the expression of FAS, FAM3B,
and TNFSF13, we first identified TCGA tumor samples
with these alterations. Out of 333 tumor samples, 88
samples had FAS deleted, 92 samples had FAM3B de-
leted, and 113 had TNFSF13 deletions. To identify
hyper-methylated samples for each gene, we selected the
top 20% of the tumor samples, i.e., 67 tumor samples
with the highest methylation at promoter probes
cg26478401 for FAS, cg22612764 for FAM3B, and
cg13829089 for TNFSF13. To be consistent with the
ELMER package, we used a 20% cutoff, which is used to
identify differentially methylated promoter and enhancer
probes with respect to normal. The 20% cutoff allows
identification of molecular subtypes making up minority
cases, while providing enough statistical power for pre-
dictions [52]. To generate the Venn diagram (Fig. 5b),
we segregated tumor samples into three categories: sam-
ples with gene deletion, hyper-methylation in promoter
regions, and samples with both deletion and hyper-
methylation. To analyze the effect of deletion and differ-
ential methylation on expression, we used level 3 PRAD
TCGA RNA-Seq data corresponding to 333 tumor sam-
ples. The Wilcoxon rank sum test was used to compare
the distribution of samples with and without deletions/
hyper-methylation.
Differential gene expression
Level 3 PRAD TCGA RNA-Seq data for 333 tumor and
the adjacent 27 normal samples were used for finding
differentially expressed genes between normal and
tumor. We performed the Wilcoxon rank sum test to
identify differentially expressed genes between normal
and tumor samples at a false discovery rate threshold of
0.0001. We obtained 7,675 genes that are either up- or
down-regulated with respect to normal.
SVs have stronger influence on TF hubs
We applied Fisher’s exact test to check whether TFs al-
tered by SVs are significantly enriched for TF hubs com-
pared to TFs altered by methylation changes. Out of 31
TFs significantly altered by genetic and epigenetic
changes, 22 TFs have significant differential methylation
in promoter or enhancer regions, nine are significantly
altered by SVs in coding or non-coding region, and none
by SNVs. Among 22 TFs, three are hubs, while six are
hubs among the nine TFs affected by SVs. We found
that TFs altered by SVs are significantly enriched for
hubs compared to TFs altered by methylation changes.
Also, five out of the six hub genes affected by SVs are
differentially expressed between tumor and normal sam-
ples (ERG p value = 0.02, TP53 p value = 8.61 × 10-6, ERF
p value = 0.05, CREB3L1 p value = 2.5 × 10-11, and
POU2F2 p value = 4.02 × 10-10).
Copy number variants in PCa have been shown to be as-
sociated with disease recurrence and metastasis [3, 81, 117].
We stratified 188 WGS and 333 TCGA tumor samples
with deletions in the five TF hubs by Gleason score and
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observed enrichment for Gleason score 8 or higher in
TCGA samples (OR = 2.13, p value = 0.003). The ab-
sence of this enrichment in WGS data could be due to
depletion of tumors with a high Gleason score in ICGC
samples (Additional file 4: Table S10).
ERF signature
To generate the ERF signatures, we analyzed the RPKM
RNA-Seq profiles of ERF shRNA knockdown in VCaP
cell lines [89]. Briefly, we independently rank genes ac-
cording to the difference of means between the shERF-
infected VCaP and control samples. The same procedure
was performed for the LHS-AR cell line. The top 100
up-regulated genes in LHS-AR and VCaP cell lines are
provided as part of the supplementary information
(Additional file 4: Table S11). We performed Fisher’s
exact test to assess whether ERG and ERF binding tar-
gets in the prostate regulatory network are enriched for
genes up-regulated due to ERF knockdown in VCaP and
LHS-AR cell lines. Out of 17,087 prostate network
genes, 5,103 are ERG binding targets and 3,327 are ERF
target genes. Among the top 100 up-regulated genes due
to ERF knockdown in VCaP, 63 are present in our pros-
tate regulatory network, 38 are ERG binding targets, and
25 are ERF targets. Similarly, among the top 100 up-
regulated genes in LHS-AR, 76 are present in the pros-
tate network, 36 are ERG target genes, and 21 are ERF
targets [VCaP: Fisher’s exact test OR = 2.38, p value =
0.00012 (ERF) and OR = 3.58, p value = 5.7 × 10-7 (ERG);
LHS-AR: Fisher’s exact test OR = 1.64, p value = 0.05
(ERF) and OR = 2.12, p value = 0.0014 (ERG)]. We would
like to note that a change in ERF expression impacts the
downstream transcriptional program through activation
of both direct and indirect binding targets. As it is hard
to compute indirect binding targets from our network,
we restrict our analysis to direct targets only.
TF expression and DNA methylation
We calculated the Spearman correlation between TF
hub expression (ERG, TP53, POU2F2, SPI1, CREB3LI,
and ERF) and DNA methylation β values at differentially
methylated probes in TF binding motifs. We correlated
ERG expression with average DNA methylation at 642
hyper-methylated and 24 hypo-methylated probes with
overlapping ERG ChIP-Seq binding peaks (GSM353647).
Due to the unavailability of ChIP-Seq peaks for the
remaining TF hubs, we considered differentially methyl-
ated probes in promoters and enhancers with a TF bind-
ing motif. All the TF binding targets in our prostate
network are enriched for TF motifs.
For this analysis, we used level 3 HM450 PRAD DNA
methylation data for 333 TCGA prostate samples and
log2-transformed level 3 PRAD TCGA RNA-Seq RSEM
data. Three out of six TF hubs showed significant
correlations between TF expression and DNA methyla-
tion at differentially methylated probes within TF bind-
ing motifs (ERG: rho = -0.173, p value = 0.00149;
POU2F2: rho = -0.277, p value = 3.01 × 10-7; SPI1: rho
= -0.14, p value = 0.010). The differential expression of
TFs with more binding sites should have a larger impact
in the network by causing methylation changes at more
sites, consistent with our observation of significant cor-
relation between TF hub expression (ERG, POU2F2, and
SPI1) and DNA methylation at binding sites. As a refer-
ence, we do not observe significant correlation between
expression of non-TF hubs (10% of the lowest out-
degree nodes) and DNA methylation at differentially
methylated probes within TF binding motifs.
RWPE1 cell line preparation
We obtained RWPE1 cells from ATCC and maintained
them as per the manufacturer’s protocol. The RWPE1-
ERG isogenic cell line with overexpressed ERG (the
common isoform is based on TMPRSS2-ERG fusion)
and the RWPE1-GFP cell line have been previously de-
scribed [97, 118]. We prepared genomic DNA from
RWPE1-GFP or RWPE1-ERG using standard phenol
chloroform extraction followed by ethanol preparation
and suspension into 30 μl of 10 mM Tris pH 8.0. The
genomic DNA used in the EpiTYPER MassARRAY assay
was collected from the RWPE1-GFP/ERG cells using a
system of purification through a column (NucleoSpin
Tissue kit, Macherey Nagel, Bethlehem, PA).
Sample preparation for ERRBS
Sample preparation was performed at Weill Cornell
Medicine Epigenomics Core as previously described [94,
95]. ERRBS is a method developed to prepare DNA for
base-pair resolution methylation sequencing analysis
based on a restriction enzyme to enrich for CpG frag-
ments [95]. This method is a modification of the original
RRBS protocol described by [119] resulting in a 2× in-
crease of CpG detection and coverage. Briefly, the sam-
ple preparation includes the following steps: (1) MspI
enzyme digestion; (2) end repair of digested DNA; (3)
adenylation; (4) adenylated DNA fragments are ligated
with pre-annealed 5-methylcytosine-containing Illumina
adapters; (5) library fragments of 150 to 400 bp are gel-
isolated from a 1.5% agarose gel (using low-range ultra-
agarose from Bio-Rad, Des Plaines, IL); (6) bisulfite con-
version was performed using the EZ DNA Methylation
Kit (Zymo Research, Irvine, CA) per the manufacturer’s
recommendation with the following changes: (i) incu-
bation after CT conversion was conducted in a thermo-
cycler (Eppendorf, Hauppauge, NY) with the following
conditions: 30 seconds at 95 °C followed by 15 minutes
at 50 °C for 55 cycles, and (ii) product elution into 40 μl
nuclease-free water; (7) polymerase chain reaction (PCR)
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amplification for each library was prepared with
FastStart High Fidelity DNA Polymerase (Roche, Indian-
apolis, IN) and 0.5 μM each of the Illumina PCR primers
PE1.0 and 2.0. The thermocycler conditions were 5
minutes at 94 °C, 18 cycles of 20 seconds at 94 °C, 30
seconds at 65 °C, 1 minute at 72 °C, followed by 3
minutes at 72 °C. PCR products were isolated using
Agencourt AMPure XP beads per the manufacturer’s
recommended protocol (Agencourt). All amplified librar-
ies underwent quality control, which involves use of a
Qubit 1.0 fluorometer and Quant-iT dsDNA HS Assay Kit
(Invitrogen, Grand Island, NY) for quantitation and bio-
analyzer visualization (Agilent 2100 Bioanalyzer; Agilent,
Santa Clara, CA).
EpiTYPER MassARRAY system
Sample preparation was performed at Weill Cornell
Medicine Epigenomics Core as described in the previous
section. Briefly, the gDNA samples are treated with bi-
sulfite to convert any non-methylated cytosine residues
into uracil. The targeted sequences are then amplified by
PCR, preserving the bisulfite-induced sequence changes.
In vitro transcription is performed and the resulting
RNA transcripts are specifically cleaved at uracil resi-
dues. The resulting fragments differ in size and mass,
depending on the sequence changes generated through
bisulfite treatment. The EpiTYPER reaction products are
dispensed onto a SpectroCHIP array and read by a
MALDI-TOF mass spectrometer for data acquisition.
The primers used to target the 17 sequences are listed in
Additional file 4: Table S12.
Computational approach for ERRBS analysis
The bisulfite-treated reads were aligned and methylation
calls were made as previously described [95]. The bisul-
fite reads were aligned to the bisulfite converted hg19
reference genome using Bismark [120]. We analyzed the
ERRBS data for both cell lines using the methylKit R
package [121]. methylKit analyzes and characterizes
genome-wide cytosine profiles from high-throughput
methylation experiments. It reads DNA methylation in-
formation from text files and performs operations such
as differential methylation analysis, sample clustering,
annotation, and DNA methylation visualization [121].
We used ERRBS output files for RWPE1-ERG and
RWPE1-GFP, which contained information about
chromosome, base, strand, coverage, cytosine frequency
(freqC), and thymine frequency (freqT). We used the
calculateDiffMeth() function to find differentially
methylated CpGs. The calculateDiffMeth() function uses
Fisher’s exact test to compare the fraction of methylated
C’s in test vs. control. methylKit uses the sliding linear
model (SLIM) method to correct p values and report q
values [121]. A CpG is defined to be differentially
methylated if the percentage methylation difference be-
tween test and control is larger than 25% and the q value
< 0.01. We used this criterion to call hyper- and hypo-
methylated regions in the RWPE1-ERG cell line with re-
spect to RWPE1-GFP (Additional file 1: Figure S11).
We compared DNA methylation in 333 TCGA pros-
tate tumor samples with the DNA methylation for the
RWPE1-ERG cell line and observed a significant correl-
ation (Additional file 1: Figure S12).
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